

S3 Table. Patient characteristics according to the first-line chemotherapy

Clinical characteristic	Single (n=772)	Doublet (n=3,429)	Doublet/Tmab (n=288)	Doublet/Novel (n=287)	Triplet (n=343)	p-value
Male sex	529 (68.5)	2,208 (64.4)	199 (69.1)	190 (66.2)	224 (65.3)	0.238
Age (yr)						
Median (range)	67 (23-91)	55 (19-91)	59 (22-89)	55 (22-77)	49 (20-72)	<0.001
≥ 65	476 (61.7)	724 (21.1)	93 (32.3)	57 (19.9)	26 (7.6)	<0.001
ECOG PS, 2/3	132 (17.1)	388 (11.3)	28 (9.8)	11 (3.8)	18 (5.3)	<0.001
Status						<0.001
Recurrent	421 (54.5)	1,188 (34.6)	80 (27.8)	50 (17.4)	19 (5.5)	
Initial metastatic	286 (37.0)	1,877 (54.7)	187 (64.9)	218 (76.0)	275 (80.2)	
Locally advanced	11 (1.4)	41 (1.2)	7 (2.4)	2 (0.7)	26 (7.6)	
Resected meta	54 (7.0)	323 (9.4)	14 (4.9)	17 (5.9)	23 (6.7)	
No. of metastasis, 2 or more	232 (30.2)	1,216 (35.7)	148 (52.1)	154 (54.0)	104 (30.5)	<0.001
Post-chemo surgery, done	0	46 (1.4)	13 (4.5)	2 (0.7)	90 (27.0)	<0.001
Prognostic score						<0.001
0-1 (good)	371 (48.1)	1,381 (40.3)	126 (43.8)	124 (43.2)	158 (46.2)	
2-3 (moderate)	283 (36.7)	1,509 (44.0)	116 (40.3)	134 (46.7)	158 (46.2)	
4 or more (poor)	118 (15.3)	536 (15.6)	46 (16.0)	29 (10.1)	26 (7.6)	
Second-line chemotherapy, Received	300 (38.9)	1,968 (57.4)	163 (56.6)	178 (62.0)	194 (56.6)	<0.001

Values are presented as number (%). ECOG PS, Eastern Cooperative Oncology Group Performance Status; Tmab, trastuzumab.